

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 11, 2004 (use as many sheets as necessary)		Application Number	09/173,531
		Filing Date	10/15/1998
		First Named Inventor	Ralph M. ELLISON
		Group Art Unit	1616
		Examiner Name	J. Pak
Attorney Docket Number	077319-0225		
Sheet	1	of	2



U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			FR 2 699 020		Eric PICHOT	12/24/1992		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
JP		International Search Report for EP 03019594 (11/4/2003).	
D		Matthew BLOCK et al., "Biological Studies with Arsenic IV. The Histopathologic Effect of Arsenic Upon the Hematopoietic Tissues of Patients with Leukemia", The Journal of Laboratory and Clinical Medicine, Vol. 41, No. 4, 4/1953, pp. 499-515.	
D		P. ROUSELLOT et al., "Arsenic derivatives: Old drugs for new indications!", Les Derives Arsenicaux: De Vieux Medicaments Pour Des Indications Renouvelees", Hematologie, Vol. 4, no. 3, 5/1998, pp. 95-97.	
D		P. ROUSELLOT et al., "Arsenic trioxide (AS2O3) and Melarsoprol induce myeloma cell apoptosis in vitro with a preferential effect on tumoral cells in patients' bone marrow", BLOOD, vol. 90, no. 10, 11/15/1997, page 325A.	
D		Z. XIE et al., "Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of BCL-2 apoptosis regulatory family", BLOOD, vol. 90, no. 10, 11/15/1997, pp. 495 A.	
D		DATABASE EPODOC 'Online! European Patent Office, the Hague, NL., CN1180563, 5/6/1998, Zhao QINGTUAN: XP002260136 *abstract*.	
JP		International Search Report for EP 03019595 (10/24/2003).	
JP		Edward B. SILBERSTEIN, "Radionuclide Therapy of Hematologic Disorders", Seminars in Nuclear Medicine, Vol. 9, No. 2, 4/1979, pp. 100-107.	
JP		David A. SEARS MD, "History of the Treatment of Chronic Myelocytic Leukemia", American Journal of the Medical Sciences, Vol. 296, No. 2, 8/1988, pp. 85-86.	

Examiner Signature		Date Considered	9/28/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: May 11, 2004

(use as many sheets as necessary)

Complete if Known

Application Number	09/173,531
Filing Date	10/15/1998
First Named Inventor	Ralph M. ELLISON
Group Art Unit	1616
Examiner Name	J. Pak
Attorney Docket Number	077319-0225



Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
DP		Zhi-Xiang SHEN et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL); II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients", Blood, Vol. 89, No. 9, 5/1997, pp. 3354-3360.	
DP		International Search Report for EP Application no. 03019628 (10/27/2003).	
DP		W. ZHANG et al., "The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms", Leukemia (1998), vol. 12, no. 9, 9/1998, pp. 1383-1391.	
DP		John G. KIDD, "EFFECTS OF ARSENIC AZOPROTEINS ON MOUSE LYMPHOMA CELLS IN VIVO* With Observations on the Effects of Other "Anti-Lymphoma" Agents and On the Susceptibility to these Effects of Lymphoma Cells of Various Types", Journal of Experimental Medicine, vol. 108, 1958, pp. 665-684.	
DP		Jacques DEBRAY, "Treatment of Hodgkin's Disease", Therapie, vol. 9, 1954, pp. 106-118.	
DP		G. LOTTI, "Abandonment of arsenic in medical therapy of malignant granuloma (Hodgkin's disease): is it justified?!" Revue Medicale Du Moyen-Orient, vol. 24, no. 2, 3/1967 pp. 110-111.	
DP		International Search Report for EP 03029713 (3/31/2004).	
		S. ROSNER, "Immunological Enhancement of Chemotherapy in Advanced Brain Cancer", ACTA Neurologica Scandinavica, vol. 21, No. 4, 1975, pp. 120-132.	
		S. SHIMOTSUURA, "STUDIES ON THE ANTINEOPLASMIC ACTIONS OF AS₂O₃" Shika Gakuho - Journal of Tokyo Dental College Society, vol. 86, no. 6, 1986, pp. 1207-1255.	
		P. ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide" Zhonghua Xueyexue Zazhi - Chinese Journal of Hematology, vol. 17, no. 2, 1996, pp. 58-60.	
DP		D.A. Sears, "History of the Treatment of Chronic Myelocytic Leukemia", American Journal of Medical Sciences, vol. 296, no. 2, 8/1988, pp. 85-86.	
DP		Y.L. KWONG et al., "Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia", Blood, vol. 89, no. 9, 5/1997, pp. 3487-3488	
		Edward B. SILBERSTEIN, "Radio nuclide Therapy of Hematologic Disorders", Seminars in Nuclear Medicine, vol. 9, no. 2, 4/1979, pp. 100-107.	

Examiner
Signature

Date
Considered

9/28/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.